Compare MGIH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | HOTH |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 12.8M |
| IPO Year | 2022 | 2018 |
| Metric | MGIH | HOTH |
|---|---|---|
| Price | $1.44 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.7K | ★ 299.9K |
| Earning Date | 10-28-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.49 |
| 52 Week High | $4.84 | $2.12 |
| Indicator | MGIH | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 31.88 |
| Support Level | $1.39 | $0.49 |
| Resistance Level | $1.58 | $0.80 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 5.26 | 15.87 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.